Daptomycin compatibility in peritoneal dialysis solutions.

摘要

Peritonitis, the most common complication of peritoneal dialysis (PD), can cause significant morbidity and mortality (1,2). If vancomycin-resistant Staphylococcus aureus peritonitis or vancomycin-resistant Enterococcus (VRE) peritonitis develops, Linezolid, daptomycin, or quinupristin-dalfopristin (Q/D) must be used. Linezolid and Q/D have limitations, including spectrum of activity and tolerability (1). Daptomycin, a cyclic lipopeptide, has been studied in an animal peritonitis model (3) and an in vitro PD fluid model (4), supporting its potential use in peritonitis. Four cases of successfultreatmentin patients with PD-related VRE peritonitis have been reported (5-7). But the peritoneal route of daptomycin administration in dialysis solution needs further exploration in terms of compatibility and stability.